Rakuten Medical



Hassan Danesi, MD, MBA

Chief Medical Officer (CMO),
Rakuten Medical, Inc.

As Chief Medical Officer, Hassan leads the global clinical development strategy and execution of Rakuten Medical's innovative Alluminox® platform-based photoimmunotherapy. Together with cross-functional teams across the organization, he is committed to advancing the clinical development of this novel therapeutic modality for cancer and expanding its potential to benefit patients worldwide.

Since joining Rakuten Medical in 2023, Hassan has overseen clinical development programs across North America, Japan, Taiwan, Eastern Europe, and the Middle East and North Africa (MENA). He has played a pivotal role in the initiation and advancement of the global ASP-1929-381 Phase 3 trial, leading enrollment efforts across multiple regions and helping strengthen the company's global clinical development capabilities. Hassan has also been instrumental in shaping development strategies evaluating the expansion of the application of Alluminox platform-based photoimmunotherapy across a broad range of cancer indications, supporting the continued growth of the company's oncology pipeline.

Prior to joining Rakuten Medical, Hassan established an extensive track record in global drug development across the biotechnology, pharmaceutical, and research sectors. He led immuno-oncology development programs at Coherus BioSciences and Adaptimmune Therapeutics and held drug development positions at multiple biotechnology companies, clinical research organizations, and academic institutions.

With more than 20 years of experience in global clinical drug development, including over 15 years leading oncology programs, Hassan has successfully advanced development programs across multiple therapeutic areas and guided product lifecycle management initiatives in both the United States and Europe.

Hassan received his MD degree from the University of Jos, Nigeria and Executive MBA from Rutgers University, U.S.

October 2026